Q-omics provides the consensus-scored PECR profile across patient tissues and cancer cell-line models. PECR expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PECR is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PECR protein abundance shows 20,225 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where PECR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PECR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PECR survival associations across molecular data types. PECR RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PECR RNA expression–survival associations across cancer types. High PECR expression shows unfavorable associations in ESCA, UVM and DLBC, but favorable associations in KIRC, LIHC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PECR RNA expression.
This table summarizes PECR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PECR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PECR shows lower tumor expression in KICH, COAD, LUSC, LUAD, BRCA and READ. The KICH box plot shows higher PECR RNA expression in normal versus tumor tissue (log2 FC = −2.498, t-test p < 0.001).
This table shows molecular features associated with PECR in patient tissues and cancer cell lines. In patient samples, PECR shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PECR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
